首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   298篇
  免费   12篇
  国内免费   14篇
儿科学   1篇
妇产科学   1篇
基础医学   36篇
口腔科学   6篇
临床医学   7篇
内科学   19篇
皮肤病学   15篇
神经病学   27篇
特种医学   10篇
外科学   2篇
综合类   23篇
预防医学   7篇
眼科学   6篇
药学   149篇
中国医学   5篇
肿瘤学   10篇
  2023年   1篇
  2022年   1篇
  2021年   8篇
  2020年   4篇
  2019年   15篇
  2018年   6篇
  2017年   9篇
  2016年   5篇
  2015年   6篇
  2014年   10篇
  2013年   23篇
  2012年   14篇
  2011年   18篇
  2010年   18篇
  2009年   10篇
  2008年   14篇
  2007年   13篇
  2006年   12篇
  2005年   15篇
  2004年   8篇
  2003年   15篇
  2002年   10篇
  2001年   5篇
  2000年   6篇
  1999年   6篇
  1998年   1篇
  1997年   8篇
  1996年   4篇
  1993年   5篇
  1992年   2篇
  1991年   3篇
  1990年   2篇
  1989年   1篇
  1987年   1篇
  1986年   2篇
  1985年   6篇
  1984年   10篇
  1983年   7篇
  1982年   6篇
  1981年   1篇
  1980年   2篇
  1979年   7篇
  1978年   2篇
  1976年   1篇
  1975年   1篇
排序方式: 共有324条查询结果,搜索用时 46 毫秒
1.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents.  相似文献   
2.
目的:研究水杨醛-N′-(2-呋喃硫羰基)腙铜配合物(CSFC)在兔体内的药物动力学。方法:10只家兔静脉注射CSFC5mg·kg-1,用反相HPLC法测定血清药物浓度。结果:CSFC的血药浓度-时间曲线符合二室开放模型,主要药动学参数为:T12α=3.4±1.7min,T12β=65.5±14.6min,K12=0.1183±0.0669min-1,K21=0.0228±0.0065min-1,K10=0.1202±0.0407min-1,V0=0.305±0.184L·kg-1,CL=1.896±0.470L·kg-1·h-1,AUC=170.1±57.0mg·min-1·L-1。结论:CSFC在兔体内分布迅速而广泛,消除也较快。家兔静注5mg·kg-1,可维持抗结核杆菌有效血浓度6h。  相似文献   
3.
介绍了一种新型的防腐杀菌剂--二羟甲基二甲海因的合成方法,采用5,-5二甲海因与甲醛在常压、碱性、冰浴下,反应2小时,产率88.6%。  相似文献   
4.
利用紫外分光光度计对二氯二茂钛进行含量测定。回归方程为 :Y =0 9881X - 0 90 90× 10 -3(Y :吸光度 ;X :浓度 ,mg/L) ,相关系数r=0 9999,线性范围为 13 .6~ 81.6mg/L。模拟试验 3份 ,回收率为 98 4 5 %~ 10 1 3 3 % ,相对标准偏差为 0 14 %~ 0 3 3 %。本实验研究了原料药二氯二茂钛的稳定性 ,结果表明不同的湿度、温度等条件对二氯二茂钛的稳定性有一定影响  相似文献   
5.
Purpose. To evaluate intestinal transport, uptake and metabolism characteristics of the bis(pivaloyloxymethyl)-ester [bis(POM)-ester] of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA]. Methods. Intestinal transport, uptake and metabolism of bis(POM)-PMEA were studied using an in vitro cell culture system of the intestinal mucosa (Caco-2 monolayers). Concentrations of bis(POM)-PMEA and its metabolites mono(POM)-PMEA and PMEA were determined using a reversed-phase HPLC method. Enzymatic stability of bis(POM)-PMEA was evaluated by incubation with purified liver carboxylesterase, homogenates of Caco-2 cells and scraped pig small intestinal mucosa. Results. The use of bis(POM)-PMEA as a prodrug of PMEA resulted in a significant increase in transport of total PMEA [bis(POM)-PMEA, mono(POM)-PMEA and PMEA] across Caco-2 monolayers. While transepithelial transport of PMEA (500 M) was lower than 0.1% during a 3 hr incubation period, transport of total PMEA after addition of bis(POM)-PMEA (100 M) amounted to 8.8% over the same incubation period. Only 23% of the amount transported appeared as intact bis-ester at the basolateral side, while 33% of this amount was free PMEA and 44% was mono(POM)-PMEA, suggesting susceptibility of the prodrug to chemical and enzymatic degradation. Uptake studies revealed that only negligible amounts of bis(POM)-PMEA (< 0.2%) were present inside the cells. Very high intracellular concentrations of PMEA were found 1.2 mM, after a 3 hr incubation with 50 M bis(POM)-PMEA), which suggests that PMEA was trapped inside the cells probably due to its negative charge. This explains that efflux of PMEA was relatively slow (25% of the intracellular amount in 3 hr). Enzymatic degradation of the prodrug by carboxylesterase was confirmed by incubation of bis(POM)-PMEA with purified enzyme (Km = 87 M and Vmax = 9.5 M/min). Incubation of bis(POM)-PMEA (10 M) with cell homogenate of Caco-2 monolayers and pig small intestinal mucosa produced similar degradation profiles. Conclusions. The use of the bis(POM)-prodrug significantly enhances the intestinal permeability of PMEA. Intracellular trapping of PMEA in the intestinal mucosa may result in slow release of PMEA to the circulation after oral administration of bis(POM)-PMEA.  相似文献   
6.
A skeletal seeking radiopharmaceutical labeled with a long-lived radionuclide was developed to evaluate regional bone formation and its subsequent resorption. The agent is [phosphonate (phenylmethylene hydroxy) bis]-I-125 or I-125 PA. Tissue distribution studies in mice (N=16) showed approximately 40% of the administered dose to be retained by the skeleton up to 336 hours post IV injection. The percentage of the dose accumulated by the thyroid gland remained at less than 0.5%, indicating minimal deiodination of the I-125 PA. Whole body retention studies in the same species revealed a triexponential release pattern with the longest component comprising 33% of the dose with a biologic half-life of 962 days. A fractured rat tibia model was studied with I-125 PA and Tc-99m MDP. Chronic loss of the I-125 PA relative to normal tibia was quantitated: five days (62.8%); 30 days (47.4%). Concomitant increased uptake of the Tc-99m MDP was observed at the fracture site relative to normal: five days (186%); 30 days (1,041%). The above data suggest that I-125 PA can be utilized to measure acute bone formation and chronic resorption.  相似文献   
7.
5-氟尿嘧啶-偕二膦酸偶合物的合成及其初步骨靶向性实验   总被引:1,自引:1,他引:1  
以5-氟尿嘧啶为原料,经加成、缩合、催化氢解等3步反应合成得到一个新的5-氟尿嘧啶-偕二膦酸偶合物,其结构经1H-NMR、IR和MS确证,并采用羟磷灰石晶体吸附实验考察其骨靶向性,结果显示目标物有较好的骨靶向性.  相似文献   
8.
In this article, construction of amperometric sensor(s) based on screen-printed carbon electrodes covered by thin layers of two types of carbon nanomaterials serving as amplifiers, and containing [Cu(bipy)2Cl]Cl∙5H2O complex is reported. Their performance and biomimetic activity towards two selected neurotransmitters (dopamine and serotonin) was studied mainly using flow injection analysis (FIA). The important parameters of FIA such as working potential, flow rate, and pH were optimized. The mechanism of the catalytic activity is explained and experimentally confirmed. It reveals that presence of hydrogen peroxide plays a crucial role which leads to answer the title question: can presented complex really be considered as a tyrosinase biomimetic catalyst or only as a redox mediator?  相似文献   
9.
10.
LMP-1 is a constitutively active Tumor Necrosis Factor Receptor analog encoded by Epstein–Barr virus. LMP-1 activation correlates with oligomerization and raft localization, but direct evidence of LMP-1 oligomers is limited. We report that LMP-1 forms multiple high molecular weight native LMP-1 complexes when analyzed by BN-PAGE, the largest of which are enriched in detergent resistant membranes. The largest of these high molecular weight complexes are not formed by purified LMP-1 or by loss of function LMP-1 mutants. Consistent with these results we find a dimeric form of LMP-1 that can be stabilized by disulfide crosslinking. We identify cysteine 238 in the C-terminus of LMP-1 as the crosslinked cysteine. Disulfide crosslinking occurs post-lysis but the dimer can be crosslinked in intact cells with membrane permeable crosslinkers. LMP-1/C238A retains wild type LMP-1 NF-κB activity. LMP-1's TRAF binding, raft association and oligomerization are associated with the dimeric form of LMP-1. Our results suggest the possibility that the observed dimeric species results from inter-oligomeric crosslinking of LMP-1 molecules in adjacent core LMP-1 oligomers.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号